Liver News and Research

RSS

ARIAD temporarily suspends commercial distribution of Iclusig drug in US

ARIAD Pharmaceuticals, Inc. today announced that it is temporarily suspending the marketing and commercial distribution of Iclusig® (ponatinib), a treatment for patients with resistant or intolerant chronic myeloid leukemia (CML) and Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL), in the United States, while it continues to negotiate updates to the U.S. prescribing information for Iclusig and implementation of a risk mitigation strategy.

31 Oct 2013

Interaction between fat cells and bacterial toxins can lead to chronic inflammation

Making fat cells immortal might seem like a bad idea to most people, but for a team of University of Iowa scientists it was the ideal way to study how the interaction between bacteria and fat cells might contribute to diabetes.

31 Oct 2013

Brain-derived neurotrophic factor may inhibit glucose intolerance after cerebral ischemia

Interestingly, a recent study found that ischemic stress causes hyperglycemia and may worsen ischemic neuronal damage. In addition, decreased insulin sensitivity after ischemic stress seems to be involved in the development of post-ischemic glucose intolerance.

30 Oct 2013

HDL-like particles could someday be used to combat atherosclerosis

A new type of "good cholesterol," made in the lab, could one day deliver drugs to where they are needed in the body to treat disease or be used in medical imaging, according to scientists.

30 Oct 2013

Protective effect of estrogen in women with NASH against development of severe fibrosis

New research suggests that estrogen protects women with nonalcoholic steatohepatitis (NASH) from severe liver fibrosis. According to the study published online in Hepatology, a journal of the American Association for the Study of Liver Diseases, men are at higher risk of more severe fibrosis compared to women prior to menopause, but liver fibrosis severity is similar in men and post-menopausal women.

30 Oct 2013

Infants who get hepatitis C from mothers during childbirth may inherit viral strain

Infants who get hepatitis C from their mothers during childbirth may inherit a viral strain that replicates more quickly than strains found in non-pregnant hosts, according to a new study published Oct. 27 in Nature Medicine.

29 Oct 2013

Temple University surgeons use CVHP Scalpel to remove inoperable metastatic Stage 4 Breast cancer

On September 18, 2013, a surgical team at Temple University Hospital, Philadelphia, Pa., performed a groundbreaking procedure on a patient who had previously been diagnosed with inoperable metastatic Stage 4 Breast cancer, using the Canady Vieira Hybrid Plasma Scalpel developed and sold by US Medical Innovations, LLC.

25 Oct 2013

Canadian Partnership Against Cancer, Heart and Stroke Foundation to improve health of Canadians

The Canadian Partnership Against Cancer and the Heart and Stroke Foundation, are pleased to announce a $16 million investment in a first of its kind partnership between the cancer and cardiovascular research communities that will strengthen our understanding of chronic disease.

24 Oct 2013

New Centre for Stratified Medicine opened in Ireland

The University of Ulster has opened a new Centre for Stratified Medicine. The only Centre of its kind in Ireland, £11.5m research facility in Derry~Londonderry puts the University at the forefront of medical research into chronic degenerative diseases.

24 Oct 2013

Scientists find disparities in regulation of transposons between humans and non-human primate cells

Researchers at the Salk Institute for Biological Studies have, for the first time, taken chimpanzee and bonobo skin cells and turned them into induced pluripotent stem cells, a type of cell that has the ability to form any other cell or tissue in the body.

24 Oct 2013

Testosterone treatment in hypogonadal men may reduce cardiovascular disease risk

Research from Boston University School of Medicine suggests that testosterone treatment in hypogonadal (testosterone deficient) men restores normal lipid profiles and may reduce the risk of cardiovascular disease. These finding currently appear online in the International Journal of Clinical Practice.

24 Oct 2013

UHN, Boehringer Ingelheim partner to improve care, education and support for hepatitis C patients

In a move to address a significant unmet need in hepatitis C in Canada, the University Health Network, together with Boehringer Ingelheim (Canada) Ltd., announced today a multi-year partnership that aims to improve care, education and support for patients with hepatitis C. The program, known as Link-C, aims to improve access to hepatitis C care and treatment in remote areas of Ontario and other parts of Canada.

23 Oct 2013

FDA grants Priority Review to Lilly's ramucirumab for treatment of advanced gastric cancer

Eli Lilly and Company today announced that the U.S. Food and Drug Administration has assigned Priority Review to the regulatory submission for ramucirumab (IMC-1121B) as a single-agent treatment for advanced gastric cancer following disease progression after initial chemotherapy.

23 Oct 2013

Fatty acid entry into cells happens by diffusion

The current global epidemic of obesity-linked diabetes and its associated consequences -cardiovascular, neurological and renal diseases - is a growing public health problem for which therapeutic options are limited.

23 Oct 2013

EORTC/GIMEMA trial shows combination of GO and chemotherapy provides no benefit for older patients with AML

Results of the randomized, phase III, EORTC/GIMEMA 06012 intergroup trial (AML-17) reported in the Journal of Clinical Oncology show that sequential combination of gemtuzumab ozogamicin (GO) and standard chemotherapy provides no benefit for older patients with acute myeloid leukemia (AML) and is too toxic for patients 70 years of age or more. GO is an antibody-drug conjugate comprised of an anti-CD33 monoclonal antibody linked to a cytotoxic agent.

23 Oct 2013

FDA seeks permanent injunction against dietary supplement manufacturer James G. Cole

The U.S. Food and Drug Administration, in a complaint filed by the U.S. Department of Justice, is seeking a permanent injunction against the dietary supplement manufacturer James G. Cole, Inc., its president, James G. Cole, and its general manager, Julie D. Graves, following the company's repeated distribution of unapproved drugs and adulterated dietary supplements in violation of the Federal Food, Drug, and Cosmetic Act.

23 Oct 2013

GenSpera presents final data from G-202 Phase I clinical trial at EORTC-NCI-AACR Symposium

GenSpera, Inc. (OTCBB:GNSZ) announced that Devalingam Mahalingam, MD, PhD, principal investigator of the G-202 Phase II trial in hepatocellular carcinoma, presented final data from the G-202 Phase I clinical trial yesterday at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Boston, MA.

23 Oct 2013

FDA grants Breakthrough Therapy designation to MK-5172/MK-8742 for chronic HCV infection

Merck, known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration has granted MK-5172/MK-8742 Breakthrough Therapy designation for treatment of chronic hepatitis C virus infection.

23 Oct 2013

Three cups of coffee per day reduce liver cancer risk by more than 50%

Coffee consumption reduces risk of hepatocellular carcinoma (HCC), the most common type of liver cancer, by about 40 percent, according to an up-to-date meta-analysis published in Clinical Gastroenterology and Hepatology, the official clinical practice journal of the American Gastroenterological Association.

23 Oct 2013

Guerbet receives FDA Orphan Drug Designation for Lipiodol Injection

Guerbet LLC, USA -- Guerbet, a pioneer in the field of contrast agents with more than 80 years of experience, announced that it has been granted Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development (OOPD) for Lipiodol (Ethiodized Oil) Injection for management of patients with known hepatocellular carcinoma (HCC).

22 Oct 2013

Liver News and Research

ARIAD temporarily suspends commercial distribution of Iclusig drug in US

Interaction between fat cells and bacterial toxins can lead to chronic inflammation

Brain-derived neurotrophic factor may inhibit glucose intolerance after cerebral ischemia

HDL-like particles could someday be used to combat atherosclerosis

Protective effect of estrogen in women with NASH against development of severe fibrosis

Infants who get hepatitis C from mothers during childbirth may inherit viral strain

Temple University surgeons use CVHP Scalpel to remove inoperable metastatic Stage 4 Breast cancer

Canadian Partnership Against Cancer, Heart and Stroke Foundation to improve health of Canadians

New Centre for Stratified Medicine opened in Ireland

Scientists find disparities in regulation of transposons between humans and non-human primate cells

Testosterone treatment in hypogonadal men may reduce cardiovascular disease risk

UHN, Boehringer Ingelheim partner to improve care, education and support for hepatitis C patients

FDA grants Priority Review to Lilly's ramucirumab for treatment of advanced gastric cancer

Fatty acid entry into cells happens by diffusion

EORTC/GIMEMA trial shows combination of GO and chemotherapy provides no benefit for older patients with AML

FDA seeks permanent injunction against dietary supplement manufacturer James G. Cole

GenSpera presents final data from G-202 Phase I clinical trial at EORTC-NCI-AACR Symposium

FDA grants Breakthrough Therapy designation to MK-5172/MK-8742 for chronic HCV infection

Three cups of coffee per day reduce liver cancer risk by more than 50%

Guerbet receives FDA Orphan Drug Designation for Lipiodol Injection

Industry Focus eBook - Analytical Chemistry (2nd Edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News